Halozyme Therapeutics (HALO) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Halozyme Therapeutics (HALO) PT Cut to $15 at Piper Jaffray
November 11, 2014 7:35 AM ESTPiper Jaffray analyst Charles Duncan lowered his price target on Halozyme Therapeutics (NASDAQ: HALO) to $15.00 (from $20.00) following Q3 results but retained an Overweight rating.
Duncan commented, "Halozyme reported 3Q earnings yesterday, ending the quarter with $135M, which we view as still potentially... More
